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Infection with high oncogenic risk human papillomavirus types is the etiological factor of cervical cancer and
a major cause of other epithelial malignancies, including vulvar, vaginal, anal, penile and head and neck carci-
nomas. These agents affect epithelial homeostasis through the expression of specific proteins that deregulate
important cellular signaling pathways to achieve efficient viral replication. Among the major targets of
viral proteins are components of the DNA damage detection and repair machinery. The activation of many of
these cellular factors is critical to process viral genome replication intermediates and, consequently, to sustain
faithful viral progeny production. In addition to the important role of cellular DNA repair machinery in the
infective human papillomavirus cycle, alterations in the expression and activity of many of its components are
observed in human papillomavirus-related tumors. Several studies from different laboratories have reported
the impact of the expression of human papillomavirus oncogenes, mainly E6 and E7, on proteins in almost all
the main cellular DNA repair mechanisms. This has direct consequences on cellular transformation since it
causes the accumulation of point mutations, insertions and deletions of short nucleotide stretches, as well as
numerical and structural chromosomal alterations characteristic of tumor cells. On the other hand, it is clear
that human papillomavirus-transformed cells depend on the preservation of a basal cellular DNA repair
activity level to maintain tumor cell viability. In this review, we summarize the data concerning the effect
of human papillomavirus infection on DNA repair mechanisms. In addition, we discuss the potential of
exploiting human papillomavirus-transformed cell dependency on DNA repair pathways as effective anti-
tumoral therapies.
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Human papillomaviruses and cancer
Human papillomaviruses (HPVs) are small, nonenveloped
viruses with a genome composed of double-stranded circular
DNA of approximately 8 kbp (1,2). HPVs belong to the
Papillomaviridae family and, to date, over 200 different types
have been identified and their genomes completely sequen-
ced (1). The HPV genome can be divided in three functional
regions. The upstream regulatory region (URR) or long
control region (LCR) is a noncoding portion encompassing
almost an eighth of the viral genome and is involved in the
regulation of viral replication and transcription. In addition,
there are two coding regions. The early (E) region harbors the
E1, E2, E4, E5, E6 and E7 early genes that are critical for
regulating viral genome replication, viral gene expression,
immune evasion and genome persistence. The late (L) region
encodes the major and minor capsid proteins from the L1
and L2 genes, respectively. These viruses display a marked
tropism for stratified epithelial tissues and are transmitted by
direct contact with infected skin and mucosa. As such, HPV
infections are associated with a variety of benign hyperpro-
liferative conditions, such as common and genital warts.
Approximately 40 HPV types infect the mucosa and skin
of the anogenital tract. These HPV types are further sub-
classified as low or high risk according to their association
with the development of cervical carcinoma and its precursor
lesions. Low-risk HPV types, such as HPV6 and HPV11, are
associated with genital warts and low-grade cervical intra-
epithelial neoplasia (CIN) (3,4). On the other hand, high-risk
HPV types, for example, HPV16, HPV18, HPV31 and HPV45,
are associated with the development of high-grade CIN and
cervical cancer. In addition, they are associated with a signif-
icant proportion of vulvar, vaginal, anal, penile and head and
neck carcinomas (5).
To establish a productive infection, HPVs have to reach
cells from the basal layer of the epithelium. These are the
only keratinocytes of the tissue that proliferate and express
the DNA replication machinery. Therefore, they provide a
permissive environment for initial viral genome replication.
The virus can reach these cells through microwounds caused
during sexual intercourse or at specific anatomical sites were
the basal layer is readily accessible, such as the squamoco-
lumnar junction (SCJ) of the cervix (6). Once in the cellDOI: 10.6061/clinics/2018/e539s
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nucleus, the HPV genome remains in the episomal state (100-
500 copies/per cell) and replicates together with the cellular
genome (7). The rest of the viral cycle, including vegetative
genome amplification, structural protein expression, virion
mounting and release, requires infected keratinocytes to
migrate through the different layers of the epithelium and
complete their differentiation program (8).
In high-grade CIN and HPV-associated tumors, viral DNA
is frequently integrated into the host cell genome. Viral
integration is an accidental event that usually disrupts the
region were the E1 and E2 genes are located, leading to
the loss of their expression. This constitutes a critical step in
HPV-associated carcinogenesis since the loss of E2 leads to
the upregulated expression of the main viral oncoproteins,
namely, E6 and E7 (9). The sustained expression of E6 and E7
ensures the existence of a cellular milieu favorable for HPV
replication in the suprabasal layers of the epithelium and is
critical in the process of HPV-mediated cell transformation
(see below) (10).
It is estimated that approximately 291 million women are
infected by genital HPV types worldwide. Each year, nearly
500,000 new cases of cervical cancer are diagnosed and over
270,000 women die from this disease around the world.
Importantly, most of the cases (B86%) and deaths (88%) occur
in developing countries (1). Collectively, cervical cancer and
the other HPV-associated malignancies represent 5.2% of all
tumors affecting humans (11).
DNA damage repair pathways and the HPV cycle
DNA contains the essential information for the formation
and function of an organism, and its preservation is critical
for survival. DNA is a fairly stable macromolecule; however,
it suffers constant attacks from extracellular and intracellular
factors that jeopardize its integrity. These factors include
chemical and physical agents, infectious agents, highly
reactive metabolic byproducts, and replication errors (12).
In fact, DNA damage is a common event in human cells. It is
estimated that each human cell suffers approximately one
million lesions in its DNA every day (13). Therefore, if DNA
damage is not efficiently repaired, the integrity of the genome
is compromised, causing the accumulation of mutations that
ultimately may lead to premature aging, cancer development
and death (14,15).
DNA repair is the process by which alterations in DNA
are reverted. Usually, this involves the action of nucleases,
helicases, ligases and DNA polymerases. Different specia-
lized DNA repair mechanisms exist in which complex
arrays of cellular proteins detect and repair different kinds
of DNA lesions (16). These mechanisms include base exci-
sion repair (BER), nucleotide excision repair (NER), DNA
mismatch repair (MMR), homologous recombination repair
(HRR) and nonhomologous end joining (NHEJ). Hereditary
or acquired defects in any of these pathways may lead
to genome instability with severe consequences for the
individual (17).
The DNA damage response (DDR) is composed of different
signal transduction pathways that include damage sensors,
signal transducers and effectors that act in a coordinated fashion
to maintain genome integrity. Some DNA lesions activate spe-
cific sensors, such as the MRN complex (Mre11-RAD50-NSB1),
replication protein A (RPA) or ATR-interacting protein (ATRIP),
that trigger signaling pathways by the phosphorylation of
apical protein kinases, such as ataxia telangiectasia mutated
(ATM), ataxia telangiectasia and Rad3 related (ATR) and
DNA-dependent protein kinase (DNA-PK). Different types of
DNA lesions activate different kinases (18,19). For instance,
double-stranded DNA breaks may activate DNA-PK or ATM.
On the other hand, single-stranded breaks preferentially acti-
vate ATR. The signaling cascade triggered by ATM and ATR
then activates downstream kinases CHK2 (checkpoint kinase
2) and CHK1 (checkpoint kinase 1), respectively. However, the
ATR-CHK1 and ATM-CHK2 pathways are not completely
independent since they exhibit a high degree of redundancy
and overlap. These pathways may regulate the phosphatase
Cdc25 and activate the transcription factor p53, leading to
cyclin-dependent kinase (CDK) inhibition and blocking cell
cycle progression by the activation of specific checkpoints.
Consequently, DNA damage effectors may mediate cell cycle
arrest to allow DNA repair or, when the amount of damage is
too high, induce cell death (14,17).
Many viruses, especially those with oncogenic properties,
express proteins that affect the cell cycle and DNA damage
repair regulatory pathways. Several studies have shown that
during genome amplification, HPV proteins interact with
different components of the cellular DNA repair machinery
to activate or downregulate the expression or activity of
factors of the ATM and ATR pathways. In 2009, Moody and
coworkers showed that ATM activation is required for
the productive genomic replication of HPV31 but not for
episomal maintenance (20). On the other hand, it was obser-
ved that CHK1 inhibition causes an important reduction in
the number of HPV episomes in differentiated cells (21). In
addition, the knockdown of DNA topoisomerase 2-binding
protein 1 (TopBP1), a protein that acts upstream of ATR, sup-
presses HPV31 replication (22). In line with these observa-
tions, it has been reported that E2 protein from HPV16
interacts with TopBP1 and that this interaction improves E2-
mediated viral transcription and replication (23). Moreover,
ATM and ATR kinases are constitutively activated in HPV-
positive keratinocytes, and ATR/CHK1 blockade is asso-
ciated with the downregulation of HPV productive replica-
tion and the reduced expression of late genes (22).
Importantly, many proteins from ATM and ATR pathways
colocalize with HPV replication sites, further supporting the
role of these factors in the HPV life cycle. Different studies
have shown that E1 and E2 early proteins may activate the
DDR, recruiting factors involved in DNA repair to process
replication intermediates during viral genome amplifica-
tion. Identified proteins at centers of HPV replication include
53BP1, ATRIP, OPbp1, p-ATM, p-H2AX, p-p53, ATR, CHK1,
CHK2, PCNA, RPA, NBS1, BRCA1, RAD51, MRE11 and
Ku70/80 (24-27) (Figure 1A). Collectively, these studies
indicate that HPV may modulate different signaling path-
ways involved in the DDR to warrant effective viral tran-
scription, faithful genome replication and, ultimately, the
production of a large number of infective virions (10,28,29).
HPV oncoproteins pave the road to genome
instability
The effect of specific HPV proteins on DNA repair path-
ways has been addressed by different groups. The HPV
genome does not express proteins capable of mediating viral
DNA replication and depends on the host cell machinery to
achieve genome amplification. Therefore, it must induce the
host cell to re-enter the S phase of the cell cycle to obtain
access to the DNA replication machinery (30). This is accom-
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plished by the action of viral proteins, mainly E6 and E7,
on cellular factors involved in cell cycle regulation. E6 and
E7 are the major HPV transforming proteins, and their
sustained expression is required to maintain the oncogenic
properties of HPV-transformed cells in most scenarios
(31-33). These proteins collaborate to immortalize primary
cells and can independently abrogate the mitotic check-
point and p53-mediated cell cycle arrest in response to
DNA damage (34,35).
Among the main targets of E6 is the tumor suppressor
protein p53. E6 forms a ternary complex with E6-associated
protein (E6AP) and p53, altering p53’s functional capacity
and inducing the degradation of this cellular protein by the
ubiquitin-mediated proteolysis pathway (36-38). In addition,
E6 from HPV16 binds the transcriptional coactivator CREB-
binding protein/p300 (CBP/p300) and downregulates its
ability to activate p53-responsive elements in the promoters
of several p53-regulated genes (39). E6 protein also upregu-
lates the expression of the catalytic subunit of telomerase
(hTERT) in primary cells and delays cell senescence (40).
Moreover, E6 targets other cellular factors, including those
regulating cell polarity (PDZ proteins), apoptosis and cell
differentiation (40,41). Similarly, E7 from high-risk HPV
types binds and induces the degradation of members of the
retinoblastoma (pRb) tumor suppressor proteins pRb1p110,
p107 and p130 (pRb2). This interrupts the interaction of pRb
proteins with members of the E2F transcription factor family.
Once free from inhibition, E2F activates the transcription of
several genes involved in S phase induction and progression,
including cyclins A and E (42,43). E7 also promotes cell
cycle progression by downregulating the activity of cyclin-
dependent kinase inhibitors (CKIs) p21 and p27 (44,45). In
addition, E7 of high-risk HPV16 and HPV31 interact with
histone deacetylases 1 and 2 (HDAC1 and HDAC2), affect-
ing the gene expression pattern of infected cells. Together,
these data show that E6 and E7 affect the proliferation and
differentiation of human keratinocytes by extending the
lifespan of these cells (46,47).
Due to their impact on different cellular pathways, HPV
oncoproteins may also promote the accumulation of genomic
alterations that contribute to malignant transformation (48-
54). For instance, Song and coworkers (55) demonstrated that
mouse cells expressing E6 and E7 from high-risk HPV types
continue to replicate DNA even in the presence of lesions
induced by ionizing radiation (IR) and accumulate large
numbers of alterations in the molecule. Similarly, HPV16 E7
expression is associated with the persistence of gH2AX and
Rad51 foci upon the exposure of head and neck cancer cells
to IR (56). Importantly, the expression of high-risk E6 and E7
proteins has been associated with the induction of DNA
breaks and a high frequency of foreign DNA integration into
host cells (35,57).
Figure 1 - Interplay between HPV and cellular DNA repair machinery during infective viral cycle and virus-mediated cell transformation.
A) During productive infection, HPV origin of replication (Ori) is triggered several times during the same cell cycle, leading to the
‘‘onion skin’’ type of DNA replication. To mediate genome amplification and process the viral genome replication intermediates, HPV
activates and recruits several components of the DNA damage response (DDR), including 53BP1, ATRIP, OPbp1, p-ATM, p-H2AX, p-p53,
ATR, CHK1, CHK2, PCNA, RPA, NBS1, BRCA1, RAD51, MRE11 and Ku70/80. HPV integration into the cellular genome may arise as
a consequence of active DNA break repair. This event leads to E2 downregulation and increases the levels of E6 and E7 transcripts
and proteins. B) In parallel to viral genome amplification, HPV oncogene expression increases the cell life span, induces alterations in
chromosome segregation, prevents apoptosis and affects DNA repair, leading to the accumulation of alterations in cellular DNA. C)
The presence of E2 protein either expressed from coexisting episomal viral genomes or derived from reinfection with the same or a
different HPV type may trigger the replication of integrated HPV genomes, causing the rapid appearance of chromosome breaks and
rearrangements, further contributing to malignant transformation. For references, see the main text.
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Several studies have shown that ATM and ATR pathways
are targeted by HPV oncoproteins. For instance, Banerjee et
al. (30) observed that the oncoprotein E7 from HPV18
induces increased levels of phosphorylated ATM and the
downstream kinases CHK1, CHK2, and JNKs (c-Jun N-
terminal kinases). It was also reported that E7 from HPV31
binds ATM, inducing its phosphorylation and activating
CHK2 (20). Another study showed that E7 from HPV16
induces the degradation of claspin, a protein from the ATR-
CHK1 pathway, attenuating the DNA damage checkpoint
(58). In addition, the results from recent studies support the
involvement of HPV in skin cancer. In this context, it was
observed that the protein E6 from HPV5 and HPV8, two
important cutaneous HPV types, reduces ATM levels and
downregulates the p300/ATR signaling axis, leading to the
persistence of DNA lesions induced by UVB light (10,59).
Finally, it was observed that E6 and E7 from HPV16 interact
with breast cancer-associated protein 1 (BRCA1), inactivating
its function in the repair of double-stranded DNA breaks (60).
Other alterations in DNA repair systems associated with
HPVs have been described by different groups. One report
has shown that oral keratinocytes immortalized with HPV16
exhibit deficiencies in the NER system and, consequently, are
unable to remove cyclobutane pyrimidine dimers (CPDs)
induced by UV light (61). A similar observation was made in
fibroblasts expressing E7 from HPV16. These cells show
defective NER activity and display a marked delay in the
removal of CPDs induced by UVB light (62). Recently, it was
observed that cells derived from squamous carcinoma of the
head and neck positive for HPV are more sensitive to
radiotherapy than HPV-negative cell lines due to a defect in
BER in the the former cells (63). This finding is also in agree-
ment with observations showing that E7 delays the repair of
DNA lesions induced by IR in culture systems and labo-
ratory animal models (56).
The oncoprotein E6 also targets DNA repair pathways. For
instance, epithelial mammary cells expressing this protein
from HPV16 exhibit a reduced capacity for removing thymine
dimers after exposure to UV light (64,65). In addition, oral
fibroblasts expressing E6 from HPV16 exhibit an impaired
ability to repair double-stranded breaks by NHEJ. Interest-
ingly, E6 achieves this effect via either p53-dependent or p53-
independent pathways (66). Moreover, it has been described
that E6 mediates O6-methylguanine DNA methyltransferase
(MGMT) degradation via the ubiquitin/proteasome path-
way in a process that requires the interaction of E6 with
E6AP. The action of MGMT, which is impaired by E6, pro-
tects cells and tissues against the effects of alkylating agents
(67). Finally, it was reported that E6 from different HPV types
targets X-ray repair cross-complementing protein 1 (XRCC1)
and inhibits its ability to repair DNA lesions (68).
These observations show that HPV infection may increase
the frequency of DNA alterations in the host cell and delay
the removal of these alterations by targeting DNA repair
pathways. In addition, by impairing cell cycle checkpoints
and apoptosis, HPV oncoproteins cause sustained prolifera-
tion while preventing cell death. Collectively, these effects
may lead to cellular alterations that give rise to precursor
lesions with a tendency for malignant progression.
HPV-mediated genome instability and cancer
During tumor evolution, cells acquire genetic alterations
that may upregulate the expression of proto-oncogenes or
induce gain-of-function mutations in these genes. In addi-
tion, mutations, deletions and alterations in the methyla-
tion pattern of promoter sequences may downregulate the
activity of tumor suppressor genes. Cells harboring these
alterations may have proliferative advantages and acquire
other phenotypical alterations, such as the capacity to invade
other tissues and organs (69). Genome instability is a defin-
ing phenotype of most malignant tumors that comprises
numerical and structural chromosomal abnormalities, as
well as microdeletions, small insertions, the duplication of
short nucleotide stretches and the accumulation of point
mutations. Alterations in the sequences or expression level
of proteins involved in DNA damage repair may result in
the accumulation of genetic modifications important for
cancer development. Normal cells exhibit an impressive
array of mechanisms to detect and repair DNA defects. How-
ever, many of these mechanisms are altered in tumors cells
(70,71). Although HPV activates several DNA repair path-
ways to assist its genome replication, as described above,
HPV-induced tumors exhibit a high degree of genome
instability. This fact seems to be critical for HPV-mediated
carcinogenesis and suggests that DNA repair is attenuated
during the steps leading from cellular transformation to
cancer onset (7,35).
In hereditary cancers, mutations transmitted from pro-
genitors predispose the host to the development of certain
types of tumors and/or increase their sensitivity to carcino-
gens. This process may involve alterations in components of
different DNA repair pathways. Several studies have sug-
gested that mutations in this group of genes may act as
cofactors in the establishment and progression of HPV-asso-
ciated tumors. For instance, patients with Fanconi anemia
(FA) or individuals carrying mutations in the breast cancer-
associated (BRCA) gene exhibit a higher risk of developing
HPV-associated cancerous lesions (72). In fact, the expression
of HPV16 E7 in FA-deficient fibroblasts is associated with an
increased number of chromosome aberrations (73). More-
over, K14E7/FancD2(-/-) mice exhibit a significantly higher
incidence of head and neck squamous cell carcinoma than
animals expressing K14E7 on a normal FancD2 background
(+/+) (74). Using a similar approach, it was observed in
FA-deficient mice that cervical tumors persisted even in the
absence of HPV16 E7 expression, supporting the notion that
FA-deficient tumors may escape from their dependency on
the viral oncogene (32). Upregulation of the FA pathway is
a frequent event in cervical SCC. In vitro data indicate that
the activation of this pathway is mediated by E7 and is
characterized by the formation of large FANCD2 foci and the
recruitment of FANCD2 and FANCD1/BRCA2 to chromatin
(73). These observations suggest that FA pathway activation
plays a role in the HPV cycle. The malfunction of this path-
way may lead to the accumulation of HPV-mediated geno-
mic alterations and the promotion of tumor development in
FA patients. Of clinical relevance, in this context, where FA
facilitates the accumulation of mutations, sustained viral
oncogene expression may no longer be required to maintain
the transformed phenotype (32).
Alterations in the expression of genes involved in DNA
damage sensing and repair are readily detected in HPV-
associated cancers and precursor lesions. A study that anal-
yzed the expression of genes involved in BER in 50 invasive
cervical cancer patients and 40 squamous intraepithelial
lesions (SILs) showed that the expression of XRCC1, ERCC2,
ERCC4 and ERCC1, at both the mRNA and protein levels,
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was downregulated in tumors and precursor lesions com-
pared to samples from control subjects (75). Recently, Seiwert
et al. (76) sequenced 617 cancer-associated genes in 120
matched head and neck squamous cell carcinoma/normal
samples, of which 42.5% were positive for HPV DNA. They
observed that HPV-positive tumors showed 5.8% of DNA
repair gene aberrations (including 7.8% of BRCA1/2 muta-
tions). In a study conducted in our laboratory, we compared
the expression pattern of 135 genes involved in DNA
damage repair/signaling between normal human keratino-
cytes and cervical cancer-derived cell lines and observed that
the mRNA levels of 18 genes are altered in HPV-transformed
cell lines (77).
Genome instability, in the context of HPV infection, may
arise through different molecular pathways. A clear example
of this is represented by the results of a study conducted by
Kadaja et al. (25). The authors reported that the ectopic
expression of HPV18 E1 and E2 triggers HPV replication
from viral-integrated HPV genomes in SiHa and HeLa cells,
leading to the accumulation of chromosome defects. Differ-
ent from the cellular origin of replication, which is activated
once per cell cycle, the viral origin of replication can be
triggered several times during the same cell cycle, leading
to the ‘‘onion skin’’ type of DNA replication. This process
generates replication intermediates that stress the DNA mole-
cules, leading to double- or single-stranded breaks and the
recruitment of DNA repair machinery that ligates loose
DNA ends and promotes chromosomal rearrangement.
These observations raise the disturbing possibility that the
coexistence of integrated and episomal HPV genomes in the
same cell may induce chromosome aberrations arising from
the integrated viral DNA. Moreover, the de novo HPV
infection of cells harboring integrated DNA genomes may
also endanger the cellular genome integrity and favor cell
transformation (Figure 1C).
Chronic inflammation also plays a major role in cancer
biology (69). This is also true for tumors associated with HPV
infection (78). For instance, cells harboring HPV16 genomes
exhibit increased levels of nitric oxide (NO), which triggers
inflammation and promotes DNA breaks (79). In addition,
extracellular factors, mainly inflammatory mediators, may
affect HPV infection outcome. For instance, it has been obser-
ved that interferon b may induce the elimination of HPV16
episomes from naturally infected cervical keratinocytes by
selecting cells with integrated viral genomes (80). In addi-
tion, interferon may induce HPV genome integration (81).
These observations suggest that chronic inflammation may
potentiate viral persistence and, consequently, lesion estab-
lishment and progression (82). Importantly, these findings
indicate that HPV therapies should be evaluated for the
potential selection of cells with integrated genomes and
increased proliferative potential.
As previously stated, HPV oncogenes E6 and E7 play a
critical role in HPV-mediated carcinogenesis by affecting
major cellular processes. The consequences of HPV oncopro-
tein actions are reflected on cellular genome homeostasis.
For instance, inhibition of the postmitotic checkpoint by
high-risk HPV E6 and E7 is associated with the induction
of polyploidy in human keratinocytes (83-85). It was also
observed that HPV16 oncoprotein expression induce super-
numerary centrosomes and multipolar mitotic spindles that
may lead to aneuploidy (49). In addition, an independent
study showed that E6 oncoprotein causes centrosome accumu-
lation, while HPV16 E7 interferes with the centrosome
duplication cycle (86). Interestingly, while E7 from HPV16
may induce the delocalization of dynein from mitotic
spindles, this has not been correlated with mitotic defects
(87) (Figure 1B).
Alterations in the regulation of the cell cycle and the
inhibition of proapoptotic factors are important underlying
events in HPV-mediated genome instability. As expected,
genomic instability is an early event during HPV infection
that precedes viral integration, the development of asso-
ciated lesions and their eventual progression to cancer
(88-90). Genomic instability is crucial in the appearance of
aneuploid cells and lesion progression (88). This is high-
lighted by the fact that highly polyploid as well as
aneuploid cells are mainly detected in high-grade cervical
lesions (91). Of note, most of the alterations described are
restricted to cells infected with high-risk HPV types and
are not detected upon infection with low-risk types (92).
Studies conducted using clinical samples have shown that
cervical tumors exhibit a plethora of chromosomal altera-
tions, including gains in 1, 3q, 5p, 6p, 7, 8q, 9q, 16q, and 20
and losses in 2q, 3p, 4q, 6q, 11q, 13q, 16, and 17 (93-98).
Finally, genomic alterations associated with HPV infection
have also been observed in tumors from different anato-
mical locations, including oral, anal, laryngeal and head
and neck neoplasias (76,99-101).
Genome instability is probably not a consequence of HPV-
mediated malignant transformation. However, it may favor
the acquisition of genetic alterations that confer growing
advantages to cells expressing viral oncogenes. In addition,
the underlying mutator phenotype may allow transfor-
med cells to adapt rapidly to the harsh conditions of the
tumor microenvironment, contributing to tumor onset and
progression.
HPV-associated disease treatment: can we target
DNA repair systems?
The data discussed above further support the established
notion that the main mechanism by which HPV induces cell
transformation is the targeting of p53 and pRb by E6 and E7,
respectively (43,102-104). Therefore, it is assumed that the
downregulation of these tumor suppressor proteins by E6
and E7 mimics the effect of inactivating mutations observed
in p53 and pRb in tumors not associated with HPV infec-
tion. Consequently, it is believed that HPV-positive cancers,
including anogenital, oropharyngeal tract and anal canal
tumors, are less likely to present p53 and pRb mutations
(105,106). Conversely, different studies have shown that
HPV-transformed cells retain the ability to respond to geno-
toxic stress by inducing a p53-mediated response. Therefore,
p53 downregulation as a consequence of HPV oncogene
action is not functionally equivalent to p53 inactivation by
mutation (107-109). This may be at least one of the under-
lying molecular mechanisms explaining why the presence
of HPV is associated with a better response to therapy and
constitutes a positive prognostic factor for patients with
oropharyngeal tumors (110).
However, the implementation of new therapeutic strate-
gies to treat HPV-associated tumors is still required. In this
context, the dependence of HPV-transformed cells on cellular
DNA repair machinery may constitute a suitable target
for intervention. In fact, inhibitors of selected molecules
involved in specific cellular pathways have been applied
for the treatment of cervical cancer in clinical trials (111,112).
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In addition, several examples of synthetic lethality involv-
ing genes from DNA damage repair systems and tumor
suppressor-regulated pathways have been described and
suggested as potential targets for cancer therapy (113).
The first case of synthetic lethality involving genes asso-
ciated with DNA damage repair was with poly(ADP-ribose)
polymerase (PARP) and breast and ovarian cancer suscept-
ibility genes BRCA1 and BRCA2 (114,115). PARP is a family
of proteins involved in several cellular processes, includ-
ing DNA repair and the maintenance of genome stability.
PARP1, the most studied member of the family, is rapidly
recruited to nicks and double-stranded breaks in cellular
DNA, where it gathers components of the DNA repair
machinery and promotes the removal of lesions (116). In fact,
cells with alterations in different DNA damage repair path-
ways exhibit increased susceptibility to the loss of PARP
activity. As expected, PARP inhibitors (iPARPs) prevent
DNA damage repair and are used in cancer therapy, parti-
cularly in tumors with germline or somatic mutations in
BRCA1/2 (117). The administration of iPARPs promotes cell
death by downregulating BER and promoting the accumula-
tion of DNA defects in the cell (116,118-121). Additionally, by
preventing DNA repair, PARP inhibition increases the
sensitivity of cells to chemotherapeutical agents that promote
DNA lesions (122).
E6 and E7 form high-risk HPV types are pleotropic proteins
that target an increasing list of cellular factors affecting their
expression and function. As such, HPV-transformed cells
exhibit major alterations in important signaling pathways
and cellular processes, including several DNA damage repair
mechanisms. This fact has consequences of clinical relevance.
For instance, patients harboring HPV-associated head and
neck squamous cell carcinoma (HNSCC) have significantly
improved survival compared with patients affected by
HPV-negative tumors. Although the molecular mechanisms
underlying this difference are not completely understood, it
is accepted that impaired DNA repair abilities, probably
due to HPVoncoproteins action, play a major role (110,123).
In fact, HPV-positive HNSCC-derived cell lines accumulate
more double-stranded DNA breaks than HPV-negative
counterparts and exhibit higher radiosensitivity (63,124).
In conclusion, HPV-transformed cells exhibit major defects
in DNA repair. Nevertheless, we anticipate that HPV-
transformed cells depend on the preservation of a basal
level of DNA repair activity meditated by cellular machi-
nery to maintain the minimal genomic stability needed for
tumor cell viability. Therefore, a great effort should be
directed toward identification of the molecular pathways
necessary for the survival HPV-driven tumor cells. This
will certainly contribute to the development of more effi-
cient antitumor therapies.
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